15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Abeona Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $20.00 to $21.00, so the covering firms are broadly aligned. The average target of $20.50 sits 241% above the current $6.01. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 1026% this year and 106% next, consensus EPS building from about $-0.09 next quarter toward $-0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Abeona Therapeutics Inc.
As of Sep, 2 of 2 firms rate ABEO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABEO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.09
Range $-0.24 – $0.09 · 3 analysts · -74% YoY
Next period, 3 analysts expect Abeona Therapeutics Inc to earn $-0.09 a share (range $-0.24 – $0.09), versus $-0.37 a year earlier. Full-year consensus is $-0.87, growing to $-0.19 the year after.
REVENUE · NEXT QUARTER
$18.5M
Range $10.2M – $31.7M · 3 analysts · +0% YoY
Revenue is expected to reach $18.5M (range $10.2M – $31.7M), +0.0% year-over-year. Full-year consensus is $54.3M, rising to $118.9M next year.
Top analysts covering Abeona Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABEO.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$28.00+366.0% to target
Overall win rate
38%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$15.00+149.6% to target
Overall win rate
34%
+ Follow
#3
Francois Brisebois
Oppenheimer · Rank #215
Buy
$16.00+166.3% to target
Overall win rate
41%
+ Follow
#4
Andreas Argyrides
Oppenheimer · Rank #242
Buy
$20.00+232.8% to target
Overall win rate
45%
+ Follow
#5
Jeff Jones
Oppenheimer · Rank #247
Buy
$21.00+249.5% to target
Overall win rate
31%
+ Follow
ABEO stock forecast FAQ
What is ABEO's average 12-month price target?+
The 2 analysts with a live target average $20.50 for Abeona Therapeutics Inc over the next 12 months, ranging from a $21.00 high to a $20.00 low.
Is ABEO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ABEO?+
The Street-high target is $21.00 (Oppenheimer), and the Street-low is $20.00 (HC Wainwright & Co.). The average of all 2 active targets is $20.50.
How many Wall Street analysts cover ABEO?+
2 analysts have an active rating on Abeona Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABEO?+
Among analysts who currently cover ABEO, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #169). Their current call is Buy with a $28.00 target.
What is Abeona Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.09 per share (range $-0.24 – $0.09) across 3 analysts. Full-year EPS is projected at $-0.87, rising to $-0.19 the following year.
How much revenue is Abeona Therapeutics Inc expected to report next quarter?+
Consensus revenue is $18.5M (range $10.2M – $31.7M). Full-year revenue is projected at $54.3M, growing to $118.9M next year.
Have analysts been upgrading or downgrading ABEO lately?+
As of Sep, 2 of 2 firms rate ABEO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABEO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
